| Catalog No. | Size | Price (USD) |
| 50622-R001-50 | 50 µL | $177.58 |
| 50622-R001-100 | 100 µL | $340.51 |
General Information
| Product name | Recombinant Anti-c-MET/HGFR Antibody, Rabbit Monoclonal |
| Validated applications | ELISA (FAQ Protocol) |
| Species reactivity | Reacts with: Mouse |
| Specificity | Mouse c-MET/HGFR |
| Immunogen | Recombinant Mouse c-Met/Met/HGFR Protein (Catalog#50622-M08H) |
| Preparation | This antibody was obtained from a rabbit immunized with purified, recombinant Mouse c-Met/Met/HGFR (rM c-Met/Met/HGFR; Catalog#50622-M08H;EDL13881.1; Met1-Asn929). |
| Source | Monoclonal Rabbit IgG Clone #001 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-c-Met Antibody; Anti-HGF Antibody; Anti-HGFR Antibody; Anti-Met Antibody; Anti-Par4 Antibody
Background Information
| Full Name | MET proto-oncogene, receptor tyrosine kinase |
| Description | Hepatocyte growth factor receptor (HGFR), also known as c-Met or mesenchymal-epithelial transition factor (MET), is a receptor tyrosine kinase (RTK) that is overexpressed and/or mutated in a variety of malignancies. HGFR protein is produced as a single-chain precursor, and HGF is the only known ligand. Normal HGF/HGFR signaling is essential for embryonic development, tissue repair, or wound healing, whereas aberrantly active HGFR has been strongly implicated in tumorigenesis, particularly in the development of invasive and metastatic phenotypes. HGFR protein is a multifaceted regulator of growth, motility, and invasion, and is normally expressed by cells of epithelial origin. Preclinical studies suggest that targeting aberrant HGFR signaling could be an attractive therapy in cancer. |
| Research Areas |
|
| Tags |
|
| References |
|
